Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Decision Diagnostics Corp (DECN)

Decision Diagnostics Corp (DECN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,032
  • Shares Outstanding, K 153,879
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta 1.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/27/14
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0327 +19.88%
on 07/17/19
0.0488 -19.67%
on 06/28/19
+0.0012 (+3.16%)
since 06/21/19
3-Month
0.0238 +64.71%
on 05/22/19
0.0600 -34.67%
on 06/10/19
-0.0108 (-21.60%)
since 04/23/19
52-Week
0.0053 +639.62%
on 10/25/18
0.0974 -59.75%
on 03/14/19
-0.0108 (-21.60%)
since 07/23/18

Most Recent Stories

More News
DECN's Appeal To Be Heard In Case Against J&J Over A Grossly Unfair Ruling And Lower Court's Termination Of The Case Against Their Court Wounded Adversary

Company's seminal appeal set to overturn lower court ruling, DECN will treat long standing issues with J&J and opportunities with platinum equity separately

DECN : 0.0392 (+5.95%)
DECN in Pact with Mega Pet Products Retailer Fetch for Pets Tripling Market For Company's Petsure Test Strips and Genultimate! 4pets Test Strips and Meters

LOS ANGELES, CA / ACCESSWIRE / June 25, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered...

DECN : 0.0392 (+5.95%)
DECN Discusses Propositions Received For Its GenUltimate TBG

LOS ANGELES, CA / ACCESSWIRE / June 7, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered...

DECN : 0.0392 (+5.95%)
DECN Sets Plan to Make Upcoming Patent Infringement Appeal Hearing and Mediation with Johnson & Johnson a Foundation for Substantial Recovery

Company Plans to Build a Foundation for Settlement of All Legal Matters by Wrapping a Legal Settlement into a Wide Ranging Pact to Include its Genultimate TBG

DECN : 0.0392 (+5.95%)
DECN's Appeal Nearing Oral Arguments in its Patent Battle with Johnson & Johnson Over the Unjust Ruling in the Nevada Lower Court

Appeals Court Set to Hear and Then Decide DECN's Seminal Legal Question at Issue in Long Simmering Patent Battle with Johnson & Johnson and its Successor

DECN : 0.0392 (+5.95%)
In Prelude to Probable Transaction DECN Decides to Infuse its Outre' Precise, TBG Technology to its GenChoice Test Strip, Now in FDA 510k Review

Company Also Plans 3Q 2019 Filing of Four Patents Covering GenUltimate TBG and GenChoice TBG Systems

DECN : 0.0392 (+5.95%)
DECN Expands Talks Involving Its GenUltimate TBG System, Balances Potential and Competing Outcomes with Recent Intro to 2nd Interested Party

Company Receives 3rd Communique from FDA for Clearance of its GenChoice Test Strip, and at the Request of Agent Paragon, DECN Revives GenPrecis Line for Big Box Sales

DECN : 0.0392 (+5.95%)
DECN Hails Completion of Its Genultimate! TBG Panacea System, 3rd Party Testing to Begin in Next 7 Days, Clinical Trials Testing to Begin in May

Equity Fund in Stealthy Move Tried to Gain Control of DECN In March, Just as a Big Box Was in Contact to Buy Genultimate TBG When Available, Sight Unseen

DECN : 0.0392 (+5.95%)
DECN Launches Its Genultimate 4Pets and Avantage Meter, Ground-Breaking Products for the Testing of Dogs, Cats and Horses, Receives First Retail Orders, Establishes Innovative Rebate Program

Launch Places DECN at the Top of Tier in the Fast Growing Pet Testing Market with Both Proprietary Products and Generics that Work on Market Leading Systems

DECN : 0.0392 (+5.95%)
DECN in Pact with Alpha Capital Anstalt

LOS ANGELES, CA / ACCESSWIRE / March 14, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan...

DECN : 0.0392 (+5.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade DECN with:

Key Turning Points

2nd Resistance Point 0.0392
1st Resistance Point 0.0392
Last Price 0.0392
1st Support Level 0.0392
2nd Support Level 0.0392

See More

52-Week High 0.0974
Fibonacci 61.8% 0.0622
Fibonacci 50% 0.0514
Fibonacci 38.2% 0.0405
Last Price 0.0392
52-Week Low 0.0053

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar